Cart (0)

cyclin B2 Inhibitors

Cyclin B2 inhibitors represent a specialized class of chemical compounds designed to target and modulate the activity of cyclin B2, a regulatory protein integral to cell cycle progression, specifically during the G2/M transition. Cyclin B2 is a member of the B-type cyclins, which form complexes with cyclin-dependent kinases (CDKs) to regulate various checkpoints within the cell cycle. The inhibition of cyclin B2 disrupts its association with CDK1, a critical kinase that orchestrates the entry into mitosis by phosphorylating key substrates involved in chromosomal condensation, nuclear envelope breakdown, and spindle assembly. By inhibiting cyclin B2, these compounds effectively alter the timing and fidelity of cell division, leading to significant disruptions in cellular proliferation. This disruption is a key aspect of studying cyclin B2's role in the fundamental processes of mitosis and understanding the broader implications of cell cycle control mechanisms. Structurally, cyclin B2 inhibitors are diverse and can range from small molecules to larger, more complex entities such as peptides or nucleic acid-based compounds. These inhibitors typically feature functional groups capable of interacting with the cyclin B2 binding site, either through direct binding or by allosteric modulation. The specificity of these interactions is crucial, as cyclin B2 shares significant structural homology with other cyclins, particularly cyclin B1, making the design of selective inhibitors a challenging yet rewarding endeavor. Researchers focus on optimizing these interactions to achieve high selectivity, ensuring that the inhibitors specifically target cyclin B2 without affecting other cyclin-CDK complexes. Additionally, the structural study of these inhibitors provides valuable insights into the dynamic conformational changes of cyclin B2 during its interaction with CDK1, contributing to a deeper understanding of the molecular intricacies that govern cell cycle regulation.

Items 1 to 10 of 12 total

Display:

Product Name	CAS #	Catalog #	QUANTITY	Price	Citations	RATING
Simvastatin	79902-63-9	sc-200829 sc-200829A sc-200829B sc-200829C	50 mg 250 mg 1 g 5 g	$31.00 $89.00 $135.00 $443.00	13	(1)
Simvastatin is an indirect apoD inhibitor that modulates the mevalonate pathway. By inhibiting HMG-CoA reductase, Simvastatin disrupts cholesterol biosynthesis, influencing cellular processes that may indirectly impact apoD.
GW 3965 hydrochloride	405911-17-3	sc-224011 sc-224011A sc-224011B	5 mg 25 mg 1 g	$140.00 $483.00 $3121.00		(1)
GW3965 is an indirect apoD inhibitor that activates LXR receptors. By binding to LXRs, it modulates cholesterol homeostasis and lipid metabolism, indirectly influencing apoD expression and function.
C75 (racemic)	191282-48-1	sc-202511 sc-202511A sc-202511B	1 mg 5 mg 10 mg	$72.00 $206.00 $290.00	9	(1)
C75 is an indirect apoD inhibitor that targets FAS, a key enzyme in lipid biosynthesis. By inhibiting FAS, C75 modulates lipid metabolism, potentially affecting apoD levels and functions indirectly.
Betulinic Acid	472-15-1	sc-200132 sc-200132A	25 mg 100 mg	$117.00 $344.00	3	(1)
Betulinic acid is an indirect apoD inhibitor that influences the PI3K-Akt pathway. By modulating Akt activation, it may indirectly impact apoD expression and function, although the exact mechanisms need further elucidation.
Imipramine hydrochloride	113-52-0	sc-207753 sc-207753B sc-207753A	100 mg 1 g 5 g	$26.00 $45.00 $103.00	5	(1)
Imipramine is an indirect apoD inhibitor that affects the ERK1/2 pathway. By modulating ERK1/2 activation, it may indirectly influence apoD expression and function, although the specific mechanisms require further investigation.
Fenofibrate	49562-28-9	sc-204751	5 g	$41.00	9	(1)
Fenofibrate is an indirect apoD inhibitor that activates PPARα. By binding to PPARα, it modulates lipid metabolism and may indirectly impact apoD expression and function through alterations in cellular lipid profiles.
TOFA (5-(Tetradecyloxy)-2-furoic acid)	54857-86-2	sc-200653 sc-200653A	10 mg 50 mg	$97.00 $374.00	15	(1)
TOFA is an indirect apoD inhibitor that targets ACC, a key enzyme in fatty acid synthesis. By inhibiting ACC, TOFA modulates lipid metabolism, potentially affecting apoD levels and functions indirectly.
PI-103	371935-74-9	sc-203193 sc-203193A	1 mg 5 mg	$33.00 $131.00	3	(1)
PI-103 is an indirect apoD inhibitor that targets the PI3K-Akt pathway. By inhibiting PI3K, it may indirectly influence apoD expression and function, although the specific mechanisms require further elucidation.
U-0126	109511-58-2	sc-222395 sc-222395A	1 mg 5 mg	$64.00 $246.00	136	(2)
U0126 is an indirect apoD inhibitor that affects the ERK1/2 pathway. By inhibiting MEK, it may indirectly influence apoD expression and function, although the exact mechanisms need further elucidation.
PD 98059	167869-21-8	sc-3532 sc-3532A	1 mg 5 mg	$40.00 $92.00	212	(2)
PD98059 is an indirect apoD inhibitor that modulates the ERK1/2 pathway. By inhibiting MEK, it may indirectly influence apoD expression and function, although the specific mechanisms require further investigation.

Santa Cruz Animal Health is a leading provider of animal health care products. ©2026 Santa Cruz Biotechnology Inc. All Rights Reserved.
Toll-Free: 1-800-457-3801 - Terms & Conditions | Privacy Policy | Legal
“Santa Cruz Animal Health”, “San Juan Ranch”, the San Juan Ranch logo, “UltraCruz”, “Supplement of Champions”, are registered trademarks of Santa Cruz Biotechnology, Inc. All other trademarks are the property of their respective owners.

cyclin B2 Inhibitors

Simvastatin

GW 3965 hydrochloride

C75 (racemic)

Betulinic Acid

Imipramine hydrochloride

Fenofibrate

TOFA (5-(Tetradecyloxy)-2-furoic acid)

PI-103

U-0126

PD 98059